ProPhase Labs (PRPH) Stock Price, News & Analysis

Company Overview

ProPhase Labs, Inc. (NASDAQ:PRPH) is a U.S.-based life sciences company specializing in the development, manufacture and distribution of healthcare products across prescription, over-the-counter (OTC) and nutritional supplement markets. The company’s product portfolio encompasses cold and flu remedies, dietary supplements, functional gummy vitamins and rapid diagnostic solutions. Leveraging in-house research and development capabilities, ProPhase Labs designs proprietary formulations that address key consumer wellness needs, including immune support, digestive health and joint comfort.

ProPhase Labs operates two primary business segments. The product segment delivers branded and private-label nutraceuticals, OTC medications and food supplements through relationships with national retailers, specialty chains and e-commerce platforms. The licensing segment generates revenue by out-licensing intellectual property rights to generic drug manufacturers for select formulations. State-of-the-art production facilities in New Jersey and Florida support large-scale manufacturing, quality testing and regulatory compliance for both domestic and international customers.

Since its founding in the early 1980s, ProPhase Labs has evolved from a regional contract manufacturer into an integrated health-science organization. The company has secured multiple patents covering novel gummy delivery systems and botanical extracts, and continues to invest in advanced formulation science. Geographic reach extends beyond North America into Europe and Asia-Pacific markets through a network of distributors, strategic partnerships and online channels.

Under the leadership of Chief Executive Officer John Panichella, ProPhase Labs emphasizes operational agility, rigorous quality standards and innovation. The senior management team brings decades of combined experience in pharmaceutical development, nutraceutical marketing and diagnostic testing. This expertise has enabled the company to respond swiftly to shifting consumer trends and global health challenges while maintaining steady growth in its core supplement and OTC businesses.

Key Stats

• Today's Range: $0.42 to $0.44
• 50-Day Range: $0.27 to $0.44
• 52-Week Range: $0.22 to $3.45
• Volume: 354,394 shs
• Average Volume: 3.16 million shs
• Market Capitalization: $17.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ProPhase Labs Stock Analysis - MarketRank™

ProPhase Labs scored higher than 11% of companies evaluated by MarketBeat, and ranked 883rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for ProPhase Labs.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ProPhase Labs are expected to grow in the coming year, from ($1.27) to ($0.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ProPhase Labs is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ProPhase Labs is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ProPhase Labs has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.93% of the float of ProPhase Labs has been sold short.

Short Interest Ratio / Days to Cover

ProPhase Labs has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProPhase Labs has recently increased by 604.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ProPhase Labs does not currently pay a dividend.

Dividend Growth

ProPhase Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.93% of the float of ProPhase Labs has been sold short.

Short Interest Ratio / Days to Cover

ProPhase Labs has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProPhase Labs has recently increased by 604.68%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

ProPhase Labs has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for ProPhase Labs this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ProPhase Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.60% of the stock of ProPhase Labs is held by insiders.

Percentage Held by Institutions

Only 9.45% of the stock of ProPhase Labs is held by institutions.

PRPH Stock Analysis - Frequently Asked Questions

How have PRPH shares performed this year?

ProPhase Labs' stock was trading at $0.7571 at the beginning of the year. Since then, PRPH shares have decreased by 44.1% and is now trading at $0.4235.

How were ProPhase Labs' earnings last quarter?

ProPhase Labs, Inc. (NASDAQ:PRPH) issued its quarterly earnings results on Tuesday, May, 20th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.06. The business had revenue of $1.43 million for the quarter, compared to the consensus estimate of $2.45 million.
Read the conference call transcript.

How do I buy shares of ProPhase Labs?

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ProPhase Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProPhase Labs investors own include Meta Platforms (META), Pfizer (PFE), Valero Energy (VLO), CymaBay Therapeutics (CBAY), Catalyst Pharmaceuticals (CPRX) and Energy Transfer (ET).

Company Calendar

• Last Earnings: 5/20/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRPH
• CIK: 868278
• Web: www.prophaselabs.com
• Phone: (215) 345-0919
• Fax: 215-345-5920
• Employees: 130
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$53.36 million
• Net Margins: N/A
• Pretax Margin: -665.83%
• Return on Equity: -184.38%
• Return on Assets: -64.59%

Debt

• Debt-to-Equity Ratio: 0.30
• Current Ratio: 1.03
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $6.77 million
• Price / Sales: 2.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.25 per share
• Price / Book: 1.69

Miscellaneous

• Outstanding Shares: 41,540,000
• Free Float: 37,553,000
• Market Cap: $17.59 million
• Optionable: Optionable
• Beta: -0.41